Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
|Articles|December 2, 2011
- Pharmaceutical Technology-12-02-2011
- Volume 35
- Issue 12
Pharmaceutical Technology, December 2011 Issue (PDF)
Click the title above to open the Pharmaceutical Technology December 2011 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 15 years ago
Contract API Manufacturing: The Year in Reviewalmost 15 years ago
Troublesome Signs for Bio/Pharmaceutical R&Dalmost 15 years ago
Buzz Off the Productalmost 15 years ago
PQRI Case Study (7): PackOut Remedies to Minimize Contamination and Exposurealmost 15 years ago
Inside IPEC: IPEC Tackles Monographs, Impurities, Particles, and Morealmost 15 years ago
FDA Revamps to Meet New Challengesalmost 15 years ago
In the Spotlight December 2011almost 15 years ago
Auditing by the Numbersalmost 15 years ago
Views from Pharma Leaders: A Year in Review and a Look ForwardAdvertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
3
Formulation Strategies for Next-Generation Multiagonists
4
First-in-Human Trial Speed: Why FDA Trails China
5